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Abstract
Background Percutaneous coronary intervention (PCI) in
bifurcated lesions with second-generation drug-eluting
stents (DES) was associated with increased myocardial
infarction (MI) rates. Flexible stent designs that accom-
modate well to vessel tapering may be of benefit in chal-
lenging anatomies such as bifurcated target lesions, but so
far data are scarce.
Methods We analyzed the 2-year follow-up data of the
DUTCH PEERS (TWENTE II) trial, which randomized
1811 all-comer patients to PCI with newer generation
resolute integrity zotarolimus-eluting (Medtronic) or pro-
mus element everolimus-eluting stents (Boston Scientific).
In bifurcated lesions, provisional stenting was generally
performed. Target vessel failure is a composite endpoint,
consisting of cardiac death, target vessel MI, or target
vessel revascularization.
Results Patients with at least one bifurcated lesion
(n = 465, 25.7 %) versus patients with non-bifurcated
target lesions only (n = 1346, 74.3 %) showed similar
rates of clinical endpoints including target vessel failure
(9.2 versus 7.9 %, p = 0.36) and definite stent thrombosis
(0.4 versus 1.0 %, p = 0.38). Target vessel MI was more
common in patients with bifurcated lesions (3.4 versus
1.6 %, p = 0.02); but after multivariate analysis with
propensity score adjustment, bifurcation treatment was
found not to be an independent predictor of target vessel
MI (HR 1.40, 95 % CI 0.71–2.76; p = 0.34). Among
patients with bifurcated lesions, DES type and side-branch
size did not affect outcome, but periprocedural MI occurred
more often after two-stent approaches (9.0 versus 2.1 %;
p = 0.002).
Conclusion All-comer patients treated for bifurcated and
non-bifurcated target lesions showed similar and low rates
of clinical endpoints, suggesting that the DES used are
efficacious and safe for treating bifurcated target lesions.
Keywords Bifurcation/coronary bifurcation  Drug-
eluting stents (DES)  Percutaneous coronary intervention
(PCI)  DUTCH PEERS (TWENTE II) randomized clinical
trial  Promus element platinum–chromium everolimus-
eluting stent (PE-PtCr-EES)  Resolute integrity cobalt–
chromium zotarolimus-eluting stent (RI-CoCr-ZES)
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Introduction
Stenting of bifurcated target lesions is among the most
challenging procedures in the field of percutaneous coro-
nary intervention (PCI) [1, 2]. In bifurcated lesions, the
introduction of the first generation of drug-eluting stents
(DES) reduced the need for repeat revascularization as
compared to the previously used bare metal stents [2–8].
DES of the second generation, which employed coatings
with an improved biocompatibility and thinner struts than
the first generation, have shown favorable clinical results in
both broad patient populations [9–18] and bifurcated
lesions [19–21]. Despite generally encouraging clinical
outcomes, the rate of myocardial infarction (MI), in par-
ticular of periprocedural MI (PMI), was still higher fol-
lowing stenting of bifurcated lesions as compared to non-
bifurcated lesions [20, 21].
Recently, novel DES have been developed with thinner
struts and/or more flexible stent designs that accommodate
well to vessel tapering, which may be of benefit in chal-
lenging anatomies such as bifurcated lesions [22, 23]. The
DUTCH PEERS randomized trial compares two such DES
in an all-comer patient population and has shown similar
and favorable results for both devices up to 2-year follow-
up in the overall study population [24, 25].
While the use of highly flexible DES has resulted in an
overall low MI rate [24], it is unknown whether the
implantation of such modern stents may still be associated
with an increased risk of MI in bifurcated target lesions. In
the present study, we assessed the hypothesis that there may
be no difference in safety and efficacy of these flexible DES
in treating patients with bifurcated versus non-bifurcated
target lesions. In addition, among patients with bifurcated
lesions, we evaluated the potential impact of stent type, side-
branch size, kissing-balloon inflation, and technical com-
plexity of the procedure on 2-year clinical outcome.
Methods
Patient population and study design
The present study was performed using the 2-year follow-
up data of the randomized, patient-blinded, multicenter
DUTCH PEERS trial [25]. Details of the DUTCH PEERS
(TWENTE II) trial (ClinicalTrials.gov NCT01331707)
have previously been reported [24]. In brief, the trial
compares (1:1 randomization) the resolute integrity zotar-
olimus-eluting cobalt–chromium stent (Medtronic Vascu-
lar, Santa Rosa, CA) and the promus element everolimus-
eluting platinum–chromium stent (Boston Scientific, Nat-
ick, MA) in 1811 all-comer patients. Patients were enrolled
between November 25, 2010 and May 24, 2012. The trial
complies with the Declaration of Helsinki and was
approved by the Medical Ethics Committee Twente and the
institutional review boards of all participating centers. All
patients provided written informed consent. Interventional
procedures and application of concomitant medication
were performed in accordance to medical guidelines,
clinical standards, and the physician’s judgment. The
generally recommended approach of bifurcation lesion
treatment was provisional stenting, but the technique of
stenting, medical treatment strategy, and use of final kiss-
ing-balloon inflation were left at the operator’s discretion
[24].
Clinical follow-up, monitoring, adjudication,
and angiographic analysis
A detailed description of the 2-year follow-up data has
previously been reported [25]. Data monitoring was per-
formed by the independent contract research organization
(CRO) Diagram (Zwolle, the Netherlands). The indepen-
dent CRO Cardialysis (Rotterdam, the Netherlands) per-
formed the processing of clinical outcome data and clinical
event adjudication. Experienced angiographic analysts
from Thoraxcentrum Twente, blinded for the stent type and
clinical outcome, performed offline quantitative coronary
angiographic analyses according to current standards for all
patients from the four study centers (Qangio XA 7.2,
Medis, Leiden, the Netherlands).
Data analysis
For the purpose of the present analysis, patients were cat-
egorized into patients with at least one bifurcated target
lesion versus patients with non-bifurcated lesions. A rele-
vant side-branch was defined, according to the definition in
the SYNTAX score, as a junction of a main vessel and a
side-branch with minimum lumen diameter C1.5 mm
(after intracoronary administration of nitrates and before
PCI), as measured by quantitative coronary angiography
[26]. Further analyses among patients with bifurcated
lesions involved comparisons between (1) the two allo-
cated stents; (2) bifurcated lesions with side-branch
C2.0 mm versus side-branch \2.0 mm, as measured by
quantitative coronary angiography; (3) the use of final
kissing-balloon inflation versus no final kissing; and (4)
single versus two-stent approach.
Clinical endpoints
Clinical endpoints were defined according to the Academic
Research Consortium (ARC), including the addendum on
myocardial infarction [27, 28]. Death was considered car-
diac, unless an evident non-cardiac cause could be
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established. Myocardial infarction (MI) was defined by any
creatine kinase concentration of more than double the
upper limit of normal with elevated values of a confirma-
tory cardiac biomarker. PMI was defined as target vessel
MI within 48 h after PCI. Stent thrombosis was classified
according to the ARC definitions. The composite endpoint
target vessel failure was defined as cardiac death, target
vessel MI, or clinically driven target vessel revasculariza-
tion. Target lesion failure was defined as a composite of
cardiac death, target vessel MI, and clinically indicated
target lesion revascularization. A patient-oriented com-
posite endpoint consisted of all-cause death, any MI, and
any repeat revascularization. Major adverse cardiac events
were classified as a composite of all-cause death, any MI,
emergent coronary artery bypass grafting, and clinically
indicated target lesion revascularization.
Statistical analysis
Data were reported as frequencies and percentages for
dichotomous and categorical variables, as mean ± stan-
dard deviation for continuous normally distributed vari-
ables and as median and inter-quartile range for not
normally distributed variables. Chi-square test and Fisher’s
exact test were used as appropriate. Differences between
groups in continuous variables were assessed with the
Student’s t test or the Wilcoxon rank-sum test. The
Kaplan–Meier method was used to calculate the time to
clinical endpoint and the Log-rank test was applied to
compare groups. Parameters were considered as potential
confounders if associations were found with a p value
B0.15 in univariate analyses. For adjustment of potential
confounders, propensity score analysis was used. The
propensity score was estimated using multiple logistic
regression analysis. Gender, clinical syndrome, RCA
treatment, LAD treatment, multivessel disease, small ves-
sel treatment, total stent length, number of stents per
patient, postdilation, and lesion length longer than 27 mm
were used to calculate the propensity score for having a
bifurcated target lesion. A multivariate Cox regression
model, including the propensity score as independent
variable, was then used to adjust for the propensity score.
All p values and confidence intervals were two-sided and
p values\0.05 were considered significant. Data analysis
was performed with SPSS (version 22.0, SPSS Inc., Chi-
cago, IL, USA).
Results
Baseline, lesion, and procedural characteristics
Of all 1811 randomized trial participants, 465 patients
(25.7 %) were treated for at least one bifurcated lesion.
Patients with bifurcated lesions were predominantly men,
presented more often with stable angina, and underwent
more often treatment of multiple vessels and lesions in left
anterior descending arteries (Tables 1, 2). Most patients
(83.2 %) were treated with single stents. If a two-stent
technique was applied, T-stenting (73.1 %) was generally
Table 1 Patient characteristics
of all study patients comparing
patients with bifurcated versus
non-bifurcated target lesions
Patient characteristics All patients
n = 1811
p
BL
n = 465
Non-BL
n = 1346
Age (years) 63.8 ± 11.3 64.0 ± 10.7 0.74
Female 100 (21.5) 389 (28.9) 0.002
BMI (kg/m2) 27.9 ± 4.5* 28.0 ± 4.8 0.71
Diabetes mellitus 83 (17.8) 241 (17.9) 0.98
Previous MI 112 (24.1) 285 (21.2) 0.19
Previous PCI 85 (18.3) 264 (19.6) 0.53
Previous CABG 42 (9.0) 131 (9.7) 0.66
Clinical syndrome at index PCI procedure
Stable angina pectoris 218 (46.9) 531 (39.5) 0.005
Unstable angina pectoris 57 (12.3) 188 (14.0)
Non-ST-elevation myocardial infarction 118 (25.4) 329 (24.4)
ST-elevation myocardial infarction 72 (15.5) 298 (22.1)
Values are mean ± SD or n (%)
BL bifurcated target lesion, CABG coronary artery bypass grafting, MI myocardial infarction, non-BL non-
bifurcated target lesion, PCI percutaneous coronary intervention
* n = 375,  n = 1049
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preferred above (mini-)crush (17.9 %), culotte (2.6 %), and
other two-stent approaches (6.4 %) (Table 2). Final kiss-
ing-balloon inflation was performed in 139 (29.9 %)
patients with bifurcated target lesions.
Among all patients with bifurcated lesions, 244
(52.5 %) were treated with resolute integrity and 221
(47.5 %) with promus element stents. The characteristics
of patients, lesions, and procedures did not differ between
the two stent groups (data not shown) except for a higher
rate of kissing-balloon inflation in resolute integrity stents
(36.1 versus 23.1 %; p = 0.002).
Clinical event rates and multivariate analysis at 2-
year follow-up
Two-year follow-up data were available for 1810 (99.9 %)
patients. Time-to-event analysis of patients with bifurcated
lesions and patients with non-bifurcated lesions showed no
Table 2 Lesion and procedural
characteristics of all study
patients comparing patients with
bifurcated versus non-bifurcated
target lesions
Lesion/procedural characteristics All patients (n = 1811) p
BL
n = 465
Non-BL
n = 1346
Multivessel treatment 123 (26.5) 173 (12.9) \0.001
Treated coronary vessels
Right coronary artery 91 (19.6) 578 (42.9) \0.001
Left anterior descending artery 336 (72.3) 518 (38.5) \0.001
Circumflex artery 148 (31.8) 375 (27.9) 0.10
De novo lesion 423 (91.0) 1204 (89.5) 0.35
Severe calcification 106 (22.8) 301 (22.4) 0.85
At least one chronic total occlusion 19 (4.1) 57 (4.2) 0.89
At least one in-stent restenosis 17 (3.7) 38 (2.8) 0.37
At least one small vessel 298 (64.1) 770 (57.2) 0.01
At least one lesion length[27 mm 95 (20.4) 223 (16.6) 0.06
Medina classification of bifurcation lesions
0.0.1 37 (8.0)
0.1.0 67 (14.4)
0.1.1 21 (4.5)
1.0.0 55 (11.8)
1.0.1 39 (8.4)
1.1.0 148 (31.8)
1.1.1 98 (21.1)
Total stent length 36.0 (22.0–56.0) 28.0 (18.0–48.0) \0.001
Number of stents per patient 2.1 (1.3) 1.7 (1.0) \0.001
Longest lesion length (mm) 19.4 (12.0) 18.3 (12.1) 0.09
Degree of stenosis (pre-PCI)* 70.2 (16.9) 71.1 (18.2) 0.36
Residual in-stent stenosis (post-PCI)* 17.9 (8.7) 17.3 (8.1) 0.22
Postdilation 397 (85.4) 1006 (74.7) \0.001
Stenting approach
1-stent 387 (83.2)
2-stent 78 (16.8)
T-stenting 57 (73.1)
(Mini)crush 14 (17.9)
Culotte 2 (2.6)
Other 5 (6.4)
Final kissing-balloon inflation 139 (29.9)
Values are mean ± SD, n (%), or median (IQR)
BL bifurcated target lesion, non-BL non-bifurcated target lesion, PCI percutaneous coronary intervention
* A reference vessel diameter of\2.75 mm is defined as a small vessel
 In the case of multiple target lesions, the most severe diameter stenosis is presented
Clin Res Cardiol
123
significant differences in the rates of target vessel failure
(9.2 versus 7.9 %; p logrank = 0.33), cardiac death (1.7
versus 2.3 %; p logrank = 0.45), and target vessel revas-
cularization (4.5 versus 4.8 %; p logrank = 0.77) (Fig. 1).
Target vessel MI was higher in patients with bifurcation
lesions (3.4 versus 1.6 %; p logrank = 0.02) (Fig. 1;
Table 3), but after multivariate analysis with propensity
score adjustment, bifurcation treatment was found not to be
an independent predictor of target vessel MI (HR 1.40,
95 % CI 0.71–2.76; p = 0.34). The rates of definite stent
thrombosis after 2 years were low and comparable for both
patients with bifurcated and non-bifurcated lesions (0.4
versus 1.0 %; p = 0.38).
Clinical outcome among patients with bifurcated
lesions
Among patients with bifurcated target lesions, the rates
of various clinical endpoints were similar for patients
treated with resolute integrity versus promus element
stents (Table 4). There was also no significant difference
in any clinical endpoint between bifurcated lesions with
side-branch C2.0 versus \2.0 mm, and between the use
of final kissing-balloon inflation versus no use of final
kissing balloons (Table 4; Fig. 2). The use of a two-stent
approach resulted in significantly higher PMI rates
than the use of a single stent (9.0 versus 2.1 %;
p = 0.002).
Discussion
Major findings
In the present subanalysis of the DUTCH PEERS ran-
domized trial, all-comer patients treated for at least one
bifurcated lesion versus patients with non-bifurcated target
lesions showed similar 2-year rates of various clinical
endpoints. Target vessel MI was more common in patients
with bifurcation lesions (3.4 versus 1.6 %); but after mul-
tivariate analysis, bifurcation treatment was found not to be
an independent predictor of target vessel MI. Among
Fig. 1 Kaplan–Meier curves of the composite clinical endpoint target vessel failure and its individual components: a target vessel failure;
b cardiac death; c target vessel revascularization; d clinically indicated target vessel revascularization
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patients with bifurcated lesions, we found no impact of
DES type, side-branch size, or final kissing-balloon infla-
tion on various clinical endpoints. PMI was more common
among patients with bifurcation lesions treated with a two-
stent technique. Our findings suggest that the novel, flexi-
ble DES used are efficacious and safe for treating bifur-
cated target lesions.
Stent design and outcome of PCI in bifurcated
lesions
Previous studies with second-generation DES examined
devices with the same drug-eluting coatings, but rather
different designs of the stent platforms, as used in the
devices of the present study [20, 21]. In a subanalysis of the
TWENTE trial, patients treated for bifurcation lesions with
second-generation Resolute (Medtronic) or Xience V stents
(Abbott Vascular Devices, Santa Clara, CA) showed
favorable 3-year outcomes that were similar to the out-
comes in patients with non-bifurcated lesions (e.g., target
vessel failure rate 13.1 versus 12.6 %), but in patients with
bifurcated lesions the PMI rate was more than twice as high
(6.9 versus 3.1 %; p\ 0.01) [20]. These data corroborated
the results of a substudy of the RESOLUTE All Comers
trial, which had also reported a higher PMI rate in 392
patients with bifurcated lesions (6.5 versus 3.4 %; unad-
justed p = 0.009) [21]. In a pooled analysis of the
RESOLUTE All Comer trial and the RESOLUTE Inter-
national Registry, the incidence of target lesion failure and
the individual components thereof was higher during the
first 30 days after PCI of patients who were treated for
bifurcation lesions as compared to patients treated for non-
bifurcated lesions. However, during the remainder of the
3-year follow-up, clinical event rates were similar for both
patient groups [29]. PMI in treatment of bifurcated lesions
may result from (stent-induced) closure of side-branches,
flow-limiting dissections, distal (micro)embolization of
atherothrombotic debris, and the occurrence of slow flow
or no-reflow [20, 30].
The development of newer-generation DES and the
progression into devices with highly flexible stent plat-
forms have reduced the need for repeat revascularization
and the rate of target vessel MI following PCI of bifurcated
lesions [3–9, 11, 19–22, 31]. Burzotta et al. used virtual
bench tests to assess the impact of technical characteristics
of DES platforms on stenting in bifurcated lesions, show-
ing that technical features of DES platforms lead to dif-
ferences in response to similar procedural steps of
provisional stenting, such as final kissing-balloon inflation
[23]. Therefore, technical characteristics of stents should
be taken into account in the selection process of the most
appropriate DES for treatment of bifurcated lesions [23].
Both resolute integrity and promus element stents have
demonstrated favorable results in the all-comer patient
population of the DUTCH PEERS randomized trial [24].
The present study of patients with bifurcated lesions has
shown similar rates of various clinical endpoints for both
stent groups. The baseline characteristics of patients with
bifurcated lesions in both DES arms were comparable, but
in promus element stents final kissing-balloon inflation was
Table 3 Two-year clinical
outcome in patients with
bifurcated lesions versus non-
bifurcated lesions
All patients
n = 1810
p
BL
n = 465
Non-BL
n = 1345
Cardiac death 8 (1.7) 31 (2.3) 0.45
Target vessel myocardial infarction 16 (3.4) 22 (1.6) 0.02
Periprocedural myocardial infarction* 15 (3.2) 15 (1.1) 0.002
Target vessel revascularization 21 (4.5) 65 (4.8) 0.78
Target lesion revascularization 16 (3.4) 50 (3.7) 0.78
Definite stent thrombosis 2 (0.4) 13 (1.0) 0.38
Definite or probable stent thrombosis 4 (0.9) 16 (1.2) 0.56
Target vessel failure 43 (9.2) 106 (7.9) 0.36
Target lesion failure 38 (8.2) 93 (6.9) 0.37
Major adverse cardiac events 43 (9.2) 112 (8.3) 0.54
Patient-oriented composite endpoint 60 (12.9) 168 (12.5) 0.82
Values are n (%)
Two-year follow-up was available for 1810 of 1811 patients (99.9 %)
BL bifurcated target lesion, Non-BL non-bifurcated target lesion
* Periprocedural myocardial infarction is a sub-classification of (any) target vessel myocardial infarction;
 clinically indicated
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Table 4 Two-year clinical outcome in patients among patients treated for bifurcated lesions
Patient characteristics Stent used
n = 465
Maximum side-branch (SB)
diameter (mm) n = 465
Kissing-balloon inflation
n = 465
Stenting approach
n = 465
Resolute
integrity
n = 244
Promus
element
n = 221
p SB\ 2.0
n = 123
SB C 2.0
n = 342
p KB
n = 139
No KB
n = 326
p 1-Stent
n = 387
2-Stent
n = 78
p
Cardiac death 4 (1.6) 4 (1.8) 1.00 0 8 (2.3) 0.12 1 (0.7) 7 (2.1) 0.45 7 (1.8) 1 (1.3) 1.00
Target vessel
myocardial
infarction
9 (3.7) 7 (3.2) 0.76 3 (2.4) 13 (3.8) 0.58 6 (4.3) 10 (3.1) 0.50 9 (2.3) 7 (9.0) 0.003
Periprocedural
myocardial
infarction*
9 (3.7) 6 (2.7) 0.55 3 (2.4) 12 (3.5) 0.57 6 (4.3) 9 (2.8) 0.39 8 (2.1) 7 (9.0) 0.002
Target vessel
revascularization
12 (4.9) 9 (4.1) 0.66 7 (5.7) 14 (4.1) 0.46 4 (2.9) 17 (5.2) 0.27 5 (3.6) 17 (5.2) 0.45
Target lesion
revascularization
10 (4.1) 6 (2.7) 0.41 7 (5.7) 9 (2.6) 0.11 4 (2.9) 12 (3.7) 0.88 15 (3.9) 2 (0.5) 0.75
Definite stent
thrombosis
1 (0.4) 1 (0.5) 1.00 0 2 (0.6) 1.00 0 2 (0.6) 1.00 2 (0.5) 0 1.00
Definite or probable
stent thrombosis
2 (0.8) 2 (0.9) 1.00 0 4 (1.2) 0.58 1 (0.7) 3 (0.9) 1.00 3 (0.8) 1 (1.3) 0.52
Target vessel failure 24 (9.8) 19 (8.6) 0.65 10 (8.1) 33 (9.6) 0.62 11 (7.9) 32 (9.8) 0.52 32 (8.3) 11 (14.1) 0.11
Target lesion failure 22 (9.0) 16 (7.2) 0.49 10 (8.1) 28 (8.2) 0.98 11 (7.9) 27 (8.3) 0.89 28 (7.2) 10 (12.8) 0.10
Major adverse cardiac
events
24 (9.8) 19 (8.6) 0.65 10 (8.1) 33 (9.6) 0.62 12 (8.6) 31 (9.5) 0.77 32 (8.3) 11 (14.1) 0.11
Patient-oriented
composite endpoint
33 (13.5) 27 (12.2) 0.68 12 (9.8) 48 (14.0) 0.23 13 (9.4) 47 (14.4) 0.14 47 (12.1) 13 (16.7) 0.28
Values are n (%)
KB final kissing-balloon inflation, SB side-branch
* Periprocedural myocardial infarction is a sub-classification of (any) target vessel myocardial infarction;  clinically indicated
Fig. 2 Target vessel MI rate at
2-year follow-up. BL bifurcated
target lesion, KB final kissing-
balloon inflation, MI myocardial
infarction, PE promus element,
RI resolute integrity, SB side-
branch. Two-year follow-up
was available for 1810 of 1811
patients (99.9 %)
Clin Res Cardiol
123
less often performed. As the actual motives of the operators
were not documented in this context, we can only speculate
that knowledge about the somewhat increased risk of lon-
gitudinal deformation of the promus element stent [22]
might have held some operators back from performing final
simultaneous kissing-balloon inflations.
Final kissing-balloon inflation
The potential impact of a final kissing-balloon inflation on
clinical outcome following stenting of bifurcated lesions is
still unclear [20, 32–34]. Niemela¨ et al. investigated the use
of routine final kissing-balloon inflation after successful
stenting of the main branch with a single stent. Despite a
reduced rate of angiographic side-branch (re)stenosis fol-
lowing kissing-balloon inflation, clinical outcome (PMI
was not included) was similar for patients treated with
versus without final kissing-balloon inflation [32]. Three-
year outcome data of the TWENTE trial have also shown
similar target vessel failure rates in patients with bifurcated
lesions who were treated with or without final kissing-
balloon inflation [20], while final kissing-balloon inflation
was reported to be beneficial following treatment of true
bifurcation lesions with single, predominantly first-gener-
ation DES in patients with acute coronary syndromes [34].
It is likely that the inconsistent results of final kissing-
balloon inflation with different stent types are caused by
differences in the specific technical stent characteristics,
leading to different stent strut distributions after final
kissing-balloon inflation [23].
Side-branch size
Previous studies of stenting in bifurcations used different
criteria to define relevant side-branches and studied dis-
similar patient populations, which renders comparison of
their event rates difficult [3, 8, 19, 21, 32, 35]. In contrast to
several other trials that considered side-branchesC1.75 mm
[4],C2.0 mm [5, 19, 33, 34, 36–38],C2.25 mm [31, 32, 35],
or C2.5 mm [3] as relevant, the present study defined side-
branches to be relevant if they had a minimum lumen
diameterC1.5 mm by quantitative coronary angiography, as
suggested by the investigators of the SYNTAX trial [26].
Nevertheless, when comparing clinical outcome of patients
with bifurcated lesions and side-branches\2.0 mm versus
side-branches C2.0 mm, we found no relation between the
side-branch size and the risk of various clinical endpoints
including target vessel MI.
Single versus two-stent approach
Previous studies that compared the outcome of bifurcation
treatment with two-stent strategies versus the use of a
single stent suggested more often, similar to the results of
the present substudy, a higher risk of PMI following two-
stent procedures [3, 21, 29, 35, 39]. It has been speculated
that during the more complex two-stent procedures the
longer duration of vessel instrumentation, the more fre-
quent balloon and stent passages through vessel segments
proximal to the bifurcation, and the generally higher fre-
quency of stent postdilation may contribute to the higher
PMI risk [35]. A slight disadvantage of the single-stent
approach may be the somewhat higher risk of side-branch
occlusion after stenting the main branch [37, 40]. Predic-
tors of side-branch occlusion are: a high pre-procedural
degree of side-branch stenosis; a calcified side-branch
lesion; a long obstructed side-branch segment; proximal
disease in the main branch; and treatment for an acute
coronary syndrome [40]. In such bifurcation lesions with
an increased risk of jeopardizing the side-branch, the
straightforward use of a two-stent technique will often
increase the likelihood of keeping the side-branch patent
[41].
Limitations
Because of the post hoc nature of the present analysis, the
results must be considered hypothesis generating. Never-
theless, in the absence of published data on PCI in bifur-
cated lesions with these novel, flexible DES, the findings
may be of interest. Similar to previous studies [20, 21], the
sample size of subgroups among patients with bifurcated
lesions was limited. Therefore, the results of subgroup
analyses should be interpreted with caution.
Conclusion
All-comer patients treated for bifurcated and non-bifur-
cated target lesions showed similar and low rates of clinical
endpoints, suggesting that the DES used are efficacious and
safe for treating bifurcated target lesions.
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